Navigation Links
Two-Year Data Reinforce Effect of ACTEMRA(R) (tocilizumab) in Inhibiting Progression of Joint Damage and Improving Physical Function in Rheumatoid Arthritis Patients
Date:5/24/2009

reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical outcomes. Treatments that suppress the immune system, such as ACTEMRA, may cause an increase in the risk of malignancies.

About IL-6

IL-6 is a common protein found in all joints in the body and is a natural substance that can raise inflammation. Everyone has IL-6 in their body, but people with RA may have too much. When approved, ACTEMRA will be the first and only medication to specifically target IL-6 in patients with RA.

About Rheumatoid Arthritis

RA is a progressive, systemic autoimmune disease characterized by inflammation of the membrane lining in the joints. This inflammation causes a loss of joint shape and function, resulting in pain, stiffness and swelling, ultimately leading to irreversible joint destruction and disability. Characteristics of RA include redness, swelling, pain and movement limitation around joints of the hands, feet, elbows, knees and neck that leads to loss of function. In addition, the systemic symptoms of RA include fatigue, decreased hemoglobin, osteoporosis and may contribute to shortening life expectancy by affecting major organ systems. After 10 years, less than 50 percent of patients can continue to work or function normally on a daily basis. RA affects more than 21 million people worldwide with approximately 1.3 million adults affected in the United States.

About Roche

Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. pharmaceuticals headquarters of the Roche Group, one of the world's leading research-oriented healthcare groups with core businesses in pharmaceuticals and diagnostics. For more than 100 years in the U.S., Roche has been committed to developing
'/>"/>

SOURCE Roche
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
2. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
3. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
4. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
5. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
6. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
7. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
8. Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientifics Next-Generation Taxus Liberte Stent
9. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
10. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
11. Multiple Studies Presented at San Antonio Breast Cancer Symposium Reinforce Clinical Utility of Oncotype DX(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Mass. , July 24, 2014   ndd ... function testing (PFT) employing precise ultrasound technology, announced that ... the instrument to measure Carbon Monoxide Diffusing Capacity (DLCO) ... the most comprehensive study of Chronic Obstructive Pulmonary Disease ... cause of death in the U.S. and affects millions ...
(Date:7/23/2014)... N.Y. , July 23, 2014 ... of idelalisib to treat patients with relapsed chronic ... lymphocytic lymphoma (SLL) is a significant advance for ... Idelalisib, which goes by the trade name Zydelig®, ... protein that is highly expressed in many B-cell ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, 2014 ... translational preclinical research, today unveiled their new logo and ... transformation of Surpass, corporate culture to one where our ... This press release comes on the heels of the ... to the Silicon Valley Team:  David Craig, a veteran ...
Breaking Medicine Technology:EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Feb. 15 Intra-Cellular Therapies, Inc. (ITI),announced ... its,first-in-class dual 5HT2A receptor antagonist/dopamine receptor,phosphoprotein modulator ... ITI,s family of compounds that inhibit a ... dysfunction in schizophrenia. Data,characterizing the pharmacological profile ...
... Plan Also Calls for Expansion of Business Development, Streamlining of ... ... Conference Call/Webcast at 11 a.m. EST Today -, LA JOLLA, Calif., ... strategic plan for 2008 with a focus,on clinical development activities to maximize ...
Cached Medicine Technology:Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 2Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 3Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 2TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 3TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 5TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 6
(Date:7/24/2014)... July 24, 2014 A new report ... nearly 80 percent of doctors in the U.S. have upgraded ... year. , Doctors appear to be embracing more digital options. ... time, linking them to past patient histories, the latest published ... physician. , A report from the Robert Wood Johnson ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Representatives from ... be on hand to provide educational and support resources ... Meeting next week in Colorado Springs. , The Annual ... of the most renowned neurointerventional research centers ... and innovating together (with or at) symposiums, physician meetings, ...
(Date:7/24/2014)... The Arm Lift, also known as brachioplasty, is ... from the upper arms to create a more toned, slimmed ... can become lax and may begin to sag, resulting in ... appearance of sagging upper arms, and seek treatment to restore ... is now offering brachioplasty to tighten and improve the contours ...
(Date:7/24/2014)... Colo. (PRWEB) July 24, 2014 ... Prepared to Identify and Prevent the Three Infections ... Infections?’ is a go-to guide to help ... risk factors and details basic prevention measures that ... The e-book is available for download at ...
(Date:7/24/2014)... 24, 2014 The Republic of Tea, leading ... CARDAMOM CRÈME BRÛLÉE TEA to celebrate “The Hundred-Foot Journey,” a ... and Juliet Blake. A hundred-foot journey begins in the moment ... into a new realm that is far out of your ... physical distance that materially changes the course of your life ...
Breaking Medicine News(10 mins):Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 2Health News:Doctors Embracing Changing Technologies, And Technology Brings Options to Treatment 3Health News:Brain Aneurysm Foundation Provides Key Support to NeuroIntervential Physicians 2Health News:How to Get Toned Arms With Arm Lift Procedure 2Health News:How to Get Toned Arms With Arm Lift Procedure 3Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 2Health News:New E-book Helps Nurses Identify and Prevent Three Most Common Healthcare Associated Infections 3Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3
... , WEDNESDAY, Dec. 8 (HealthDay News) -- ... of developing several invasive bacterial diseases, according to a ... found to be especially strong for children 6 years ... the risk for invasive meningococcal disease, the analysis found, ...
... 8, 2010) Jeffrey S. Upperman, MD, director of ... a call to action for filling a significant gap in ... the framework for a pediatric applied trauma research network (PATRN). ... Journal of Pediatric Surgery and the Journal ...
... breakthrough? See what the experts have to say ... Perspectives on Psychological Science . Neuroimaging: ... Special Section on fMRI ( http://pps.sagepub.com/content/5/6/714.full ) ... widespread interest following the publication of Vul et ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- The children ... pregnancy are less likely to develop atopic dermatitis in their ... Atopic dermatitis (also called atopic eczema) is a chronic and ... The condition affects up to 20 percent of children in ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- A new ... blood to scan the genome of a fetus may offer ... genetic diseases, a new study suggests. Currently, a sample ... amniocentesis or chorionic villus sampling, both of which pose a ...
... ANN ARBOR, Mich. Patients who have complications after ... even when it is clearly recommended for their diagnosis, ... Cancer Center finds. In addition, patients with complications ... chemotherapy delayed for more than 120 days after diagnosis ...
Cached Medicine News:Health News:Trauma surgeon leads call to action for pediatric applied trauma research network 2Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Surgery complications linked to chemotherapy delay, U-M study finds 2
Each handle is designed to fit a specific trephine size....
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
Medicine Products: